Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

Cited In for PubMed (Select 14593167)

1.

Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease.

Canobbio I, Abubaker AA, Visconte C, Torti M, Pula G.

Front Cell Neurosci. 2015 Mar 3;9:65. doi: 10.3389/fncel.2015.00065. eCollection 2015. Review.

2.

Platelets, a reliable source for peripheral Alzheimer's disease biomarkers?

Veitinger M, Varga B, Guterres SB, Zellner M.

Acta Neuropathol Commun. 2014 Jun 16;2:65. doi: 10.1186/2051-5960-2-65. Review.

3.

Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults.

Aberg KA, McClay JL, Nerella S, Clark S, Kumar G, Chen W, Khachane AN, Xie L, Hudson A, Gao G, Harada A, Hultman CM, Sullivan PF, Magnusson PK, van den Oord EJ.

JAMA Psychiatry. 2014 Mar;71(3):255-64. doi: 10.1001/jamapsychiatry.2013.3730.

4.

Cross-talk of membrane lipids and Alzheimer-related proteins.

Walter J, van Echten-Deckert G.

Mol Neurodegener. 2013 Oct 22;8:34. doi: 10.1186/1750-1326-8-34. Review.

5.

Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotype.

Izzo G, Forlenza OV, Santos Bd, Bertolucci PH, Ojopi EB, Gattaz WF, Kerr DS.

Clinics (Sao Paulo). 2013;68(2):277-80.

6.

Novel APP/Aβ mutation K16N produces highly toxic heteromeric Aβ oligomers.

Kaden D, Harmeier A, Weise C, Munter LM, Althoff V, Rost BR, Hildebrand PW, Schmitz D, Schaefer M, Lurz R, Skodda S, Yamamoto R, Arlt S, Finckh U, Multhaup G.

EMBO Mol Med. 2012 Jul;4(7):647-59. doi: 10.1002/emmm.201200239. Epub 2012 Apr 19.

7.

The CETP I405V polymorphism is associated with an increased risk of Alzheimer's disease.

Yu L, Shulman JM, Chibnik L, Leurgans S, Schneider JA, De Jager PL, Bennett DA.

Aging Cell. 2012 Apr;11(2):228-33. doi: 10.1111/j.1474-9726.2011.00777.x. Epub 2011 Dec 29.

8.

Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine.

Clark SL, Adkins DE, van den Oord EJ.

Schizophr Res. 2011 Nov;132(2-3):114-20. doi: 10.1016/j.schres.2011.07.031. Epub 2011 Aug 27.

9.

Genetics of age-related macular degeneration: current concepts, future directions.

Deangelis MM, Silveira AC, Carr EA, Kim IK.

Semin Ophthalmol. 2011 May;26(3):77-93. doi: 10.3109/08820538.2011.577129. Review.

10.

Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease.

Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, Mc Donald JM, Wüllner U, Glebov K, Heneka MT, Walsh DM, Zweckstetter M, Walter J.

EMBO J. 2011 Jun 1;30(11):2255-65. doi: 10.1038/emboj.2011.138. Epub 2011 Apr 28.

11.

Prenatal stress differentially alters brain-derived neurotrophic factor expression and signaling across rat strains.

Neeley EW, Berger R, Koenig JI, Leonard S.

Neuroscience. 2011 Jul 28;187:24-35. doi: 10.1016/j.neuroscience.2011.03.065. Epub 2011 Apr 7.

12.

Power and pitfalls of the genome-wide association study approach to identify genes for Alzheimer's disease.

Sherva R, Farrer LA.

Curr Psychiatry Rep. 2011 Apr;13(2):138-46. doi: 10.1007/s11920-011-0184-4. Review.

13.

Identifying gene regulatory networks in schizophrenia.

Potkin SG, Macciardi F, Guffanti G, Fallon JH, Wang Q, Turner JA, Lakatos A, Miles MF, Lander A, Vawter MP, Xie X.

Neuroimage. 2010 Nov 15;53(3):839-47. doi: 10.1016/j.neuroimage.2010.06.036. Epub 2010 Jun 22. Review.

14.

Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.

Muthian G, Mackey V, King J, Charlton CG.

Neuroscience. 2010 Sep 1;169(3):1085-93. doi: 10.1016/j.neuroscience.2010.04.080. Epub 2010 Jun 9.

15.

HH domain of Alzheimer's disease Abeta provides structural basis for neuronal binding in PC12 and mouse cortical/hippocampal neurons.

Poduslo JF, Gilles EJ, Ramakrishnan M, Howell KG, Wengenack TM, Curran GL, Kandimalla KK.

PLoS One. 2010 Jan 21;5(1):e8813. doi: 10.1371/journal.pone.0008813.

16.

Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations.

Potkin SG, Turner JA, Guffanti G, Lakatos A, Torri F, Keator DB, Macciardi F.

Cogn Neuropsychiatry. 2009;14(4-5):391-418. doi: 10.1080/13546800903059829.

17.

Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Choonara YE, Pillay V, du Toit LC, Modi G, Naidoo D, Ndesendo VM, Sibambo SR.

Int J Mol Sci. 2009 Jun 3;10(6):2510-57. doi: 10.3390/ijms10062510. Review.

18.

Autonomic dysfunction in unaffected first-degree relatives of patients suffering from schizophrenia.

Bär KJ, Berger S, Metzner M, Boettger MK, Schulz S, Ramachandraiah CT, Terhaar J, Voss A, Yeragani VK, Sauer H.

Schizophr Bull. 2010 Sep;36(5):1050-8. doi: 10.1093/schbul/sbp024. Epub 2009 Apr 14.

19.

Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis.

Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA.

Biol Psychiatry. 2009 Mar 15;65(6):489-94. doi: 10.1016/j.biopsych.2008.11.010. Epub 2008 Dec 21.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk